| Trial ID: | L2745 |
| Source ID: | NCT00464880
|
| Associated Drug: |
Aliskiren
|
| Title: |
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Type 2
|
| Interventions: |
DRUG: Aliskiren
|
| Outcome Measures: |
Primary: To investigate whether renin-inhibition using aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist irbesartan 300 mg with an equivalent potential for reno-protection | Secondary: To investigate whether combination therapy using aliskiren 300 mg daily and irbesartan 300 mg daily has a greater effect on reno-protection than either drug alone|To investigate whether aliskiren, irbesartan or the combination reduce biomarkers of inflammation and cardiovascular risk
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-09
|
| Completion Date: |
2007-11
|
| Results First Posted: |
|
| Last Update Posted: |
2007-11-29
|
| Locations: |
Novartis, Gentofte, 2820, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT00464880
|
